Hester Biosciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹98 Cr +38% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
HB

Hester Biosciences Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Hester Biosciences Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹84Cr
+2.4% YoY
+2.4% QoQ
Net profit
₹17Cr
+142.9% YoY
+750% QoQ
Margin
27%
+6 pp YoY
+4 pp QoQ
Price₹2,368
Market cap₹2.1K Cr
P/E38.7

The short version

Consolidated performance is strong, giving confidence in strategies across geographies and portfolios. Consolidated performance shows strong confidence due to effective strategies across geographies and portfolios.

From Hester Biosciences Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Consolidated performance is strong, giving confidence in strategies across geographies and portfolios.
  • Optimism about growth in remaining FY '26 quarters with normalization of institutional demand.
  • Increased momentum expected in newer markets, especially in Petcare and Poultry portfolios.
  • Expansion in African markets with a focus on localized products to drive demand.
  • Efforts underway to repurpose BSL-3 facility to broaden animal vaccine range.
  • Continued growth expected from feed supplements, disinfectants, and avian influenza vaccine launches.
  • Africa operations showing a positive turnaround and profitability supporting consolidated growth.

2 more points from Hester Biosciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The BSL-3 facility, initially developed for COVID bulk antigen manufacturing, is currently being repurposed for expanding the animal vaccine product range.
  • Permission for repurposing the BSL-3 facility is expected within the next few months.
  • The firm is focused on optimizing capacity utilization across its three plants (including Nepal) to meet rising demand, particularly in Africa.
  • The company emphasizes cost discipline, operational efficiency, and strategic geographic expansion, especially in Africa, as part of its growth approach.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • There are deferred execution and timing delays in institutional orders, especially for large immunization programs like PPR and lumpy skin disease, causing a dip in standalone performance.
  • These deferred orders are not cancellations but postponements, with expectations of execution picking up from Q2 FY '26 onwards.
  • The PPR vaccine is mainly a tender business, and the company is in regular follow-up with African agencies managing eradication programs.
  • New registrations and business are coming in from various African countries, indicating a growing order pipeline.

2 more points from Hester Biosciences Ltd's call on order book

Create a free account to keep reading this call

Hester Biosciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Hester Biosciences Ltd Q1 FY26 results — key figures

Hester Biosciences Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue8482+2.4%82+2.4%
Operating profit (EBITDA)2318+27.8%19+21.1%
Operating margin27%21%+6 pp23%+4 pp
Profit before tax2011+81.8%4+400%
Net profit (PAT)177+142.9%2+750%
EPS (₹)19.337.45+159.5%1.52+1171.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹98 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Hester Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Hester Biosciences Ltd Q1 FY26 results?

Consolidated performance is strong, giving confidence in strategies across geographies and portfolios. Consolidated performance shows strong confidence due to effective strategies across geographies and portfolios.

What is Hester Biosciences Ltd share price analysis?

Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.

Is Hester Biosciences Ltd planning capital expenditure?

The BSL-3 facility, initially developed for COVID bulk antigen manufacturing, is currently being repurposed for expanding the animal vaccine product range.

Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.